Quantum eMotion Expands Strategic Stake in Greybox Solutions to Capitalize on the Digital Therapeutics Surge
Montreal, Quebec--(Newsfile Corp. - June 30, 2025) - Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0) ("QeM" or the "Company") is pleased to announce the conversion of $350,000 in debt into equity and an additional investment of $350,000 in Greybox Solutions Inc., strengthening its position as the second-largest shareholder in the company.
This strategic investment, made at an attractive valuation, reflects QeM's strong confidence in Greybox's rapid growth trajectory and unique position in the fast-evolving Remote Care Management and Digital Therapeutics (DTx) sector. Greybox's recent launch of the secure TakeCareTM platform across Quebec leading rehabilitation centers has led to strategic commercial wins, positioning the company as a rising leader in digital health with a scalable, value-based model across Canada and beyond.
"Digital therapeutics are transforming how chronic diseases are managed and patient care is delivered," said Dr. Francis Bellido, CEO of Quantum eMotion. "Greybox has demonstrated the ability to innovate, scale, and attract world-class partners. We believe this is a rare and timely opportunity to strengthen our strategic alignment with a company poised for exponential growth."
QeM's proprietary cybersecurity platform, Sentry-Q, underpins the TakeCareTM security architecture. Built around QeM's patented Quantum Random Number Generator (QRNG) technology and post-quantum encryption, Sentry-Q ensures data confidentiality, treatment integrity, and system reliability-core requirements for scaling DTx platforms in clinical environments.
Pierre Bérubé, CEO of Greybox Solutions, commented: "We're proud to deepen our partnership with Quantum eMotion-not only as a strategic cybersecurity provider, but now also as a significant shareholder. Their Sentry-Q quantum solution plays a vital role in securing our TakeCareTM platform as we expand across healthcare networks. Welcoming QeM to our cap table reinforces a shared vision: that the future of digital therapeutics must be built on trusted, quantum-safe infrastructure. The appointment of Francis Bellido to the Board of Directors of Greybox will also bring a unique experience-based expertise and direct access to a large network in the healthcare industry."
As the DTx market is projected to grow at over 20% CAGR globally, QeM's investment not only reinforces its role as a cybersecurity leader in healthcare but also unlocks strategic exposure to a transformative sector reshaping global healthcare delivery
About Greybox Solutions
Greybox Solutions is a growing Montreal-based health technology company specializing in innovative software development to improve patients' lives. Its mission is to find digital transformation solutions to address healthcare system challenges and reduce the burden of managing chronic illnesses. Greybox distributes its digital health platform, TakeCareTM to redefine the relationship between patients and their healthcare team.
About QeM
The Company aims to address the growing demand for affordable hardware and software security for connected devices. QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random Number Generator, a security solution that exploits the built-in unpredictability of quantum mechanics and promises to provide enhanced protection for high-value assets and critical systems.
The Company intends to target highly valued Financial Services, Healthcare, Blockchain Applications, Cloud-Based IT Security Infrastructure, Classified Government Networks and Communication Systems, Secure Device Keying (IOT, Automotive, Consumer Electronics) and Quantum Cryptography.
For further information, please visit our website at https://www.quantumemotion.com/ or contact:
Francis Bellido, Chief Executive OfficerTel: 514.956.2525Email: info@quantumemotion.comWebsite: www.quantumemotion.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain forward-looking statements that are subject to known and unknown risks and uncertainties that could cause actual results to vary materially from targeted results. Such risks and uncertainties include those described in the Corporation's periodic reports, including the annual report, or in the filings made by Quantum from time to time with securities regulatory authorities.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257270
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
27 minutes ago
- New York Times
Canada's Tax U-turn Highlights Trump Tariff Tactics
An about-face by Canada amid trade negotiations with the United States was welcomed on Monday by the Trump administration as a victory. But for the Canadian government, it may have just been a calculated tactical retreat. On Friday President Trump said he was suspending trade talks because Canada was about to start collecting a tax on big American technology companies, a levy that he has criticized as a 'blatant attack.' On Sunday evening, hours before that tax came into effect, the Canadian government announced it was scrapping it. Prime Minister Mark Carney of Canada said the decision was meant to allow the resumption of trade talks with the United States. 'In our negotiations on a new economic and security relationship between Canada and the United States, Canada's new government will always be guided by the overall contribution of any possible agreement to the best interests of Canadian workers and businesses,' he said in a statement. On Monday morning, talks were back on, but the White House did not miss the opportunity to take a victory lap. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes For Votes Withheld Percent For Percent Withheld Donald J. McCaffrey 144,544,411 5,161,746 96.55% 3.45% Kelly McNeill 144,898,132 4,808,025 96.79% 3.21% Siu Lun (Dicky) To 145,379,921 4,326,236 97.11% 2.89% Kenneth Zuerblis 145,121,418 4,584,739 96.94% 3.06% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 16, 2025 (the "Information Circular"). The Information Circular is available on SEDAR+ at and on the Resverlogix website at A webcast archive of the executive presentation portion of the Meeting will be available HERE. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions — altered by serious illnesses such as cardiovascular disease — back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Investor RelationsEmail: ir@ 403-254-9252 To view the source version of this press release, please visit Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
New York Times
an hour ago
- New York Times
NHL contract grades: Term, not money, is the issue with Evan Bouchard and Oilers
Defenseman Evan Bouchard signs an four-year deal with a $10.5 million AAV with the Edmonton Oilers. Harman Dayal: Bouchard is a polarizing player. He produces points like a superstar (third-most of all NHL defensemen over the last two years, behind Cale Makar and Quinn Hughes) and has the underlying numbers of an elite No.1 defenseman, but critics argue that his offensive numbers are inflated from playing with Connor McDavid and Leon Draisaitl, and that his defensive play is too inconsistent. Advertisement The truth probably lies somewhere in between. I don't buy that Bouchard is one of the best five to 10 defensemen in the league, but he's undeniably elite offensively and he's not as much of a defensive liability as some paint him out to be. Bouchard helped the Oilers to a plus-22 goal differential at five-on-five during the team's last two playoff runs. He also isn't just a McDavid/Draisaitl merchant. Bouchard drove 56 percent of shots and has outscored opponents 11-8 when both McDavid and Draisaitl were off the ice during the team's last two playoff runs. In other words, he decisively wins his even-strength matchups, even when No.97 and No.29 are on the bench. A $10.5 million AAV is totally reasonable for Bouchard. He's worth the money. However, the problem is that the Oilers only secured four years of term. This makes Bouchard UFA-eligible at 29, when a skyrocketing cap will allow him to net another sizeable raise. That's far from ideal for the Oilers, who would have been able to net surplus value if Bouchard's $10.5 million cap hit was locked in long-term. This feels like a win for Bouchard — he negotiated the flexibility of four years to setup an astronomical pay day in the future and he didn't have time to take a discounted cap hit to compensate for the shorter term. This is still a fine contract for the Oilers, but you would have liked to see them either get more years of term at this $10.5 million AAV, or get a slightly lower cap hit if Bouchard was insistent on only signing four years. Contract grade: B- Shayna Goldman: Bouchard is an elite offensive defenseman. He can be counted to spring into plays and move the puck around, and he has a bomb of a shot. But with all that dynamic skill comes the other side of his game. The risk of a player possessing the puck a lot is, there are more opportunities to lose it. When Bouchard's in control, he can be a real difference-maker. But sometimes, his decision-making can lead to crushing mistakes. That aspect of his game has improved a lot over the years, but recency bias doesn't help. As much as he helped thread the needle offensively this spring to help the Oilers return to the Cup Final, the lasting impression from Game 6 was an outright disaster. But in the big picture, the problem is that Edmonton doesn't always have the structure to mask those mistakes. And those lapses tend to turn into glaring goals against, due to the Oilers' unstable goalie play. Advertisement So pair that with the Oilers' cap situation, and his next contract was never going to be easy to navigate. Every contract has an element of risk versus reward to balance. In Bouchard's case, it's particularly high. His game-changing offense earned him a hefty raise. His market value, according to Dom Luszcsyszyn's model, is $15.7 million, which is a truly daunting number for Edmonton considering all that can go wrong for Bouchard. So coming in over $5 million below that leaves a lot more room for surplus value. The term is the key here, though. Because as much as Edmonton is banking on Bouchard, there's a big difference between taking a leap of this magnitude for four years versus eight years. It's much less of a commitment for a player whose long-term outlook is a lot tougher to project. His top comp is John Klingberg, who was elite at his height, but then steeply declined. Shea Theodore and Kris Letang project steadier long-term outlooks. But there really aren't any other close matches after that to add to the confidence in that path. But here's the thing: As much as Edmonton buys flexibility with a four-year outlook, these next four years are absolutely pivotal. This is the Oilers' best window in the Draisaitl and McDavid window. Together, the three will take up $37 million of the cap. Add in Darnell Nurse's contract and it jumps to more than $46 million. It stresses the need for very cost-effective supporting contracts around that core, plus a cost-effective goalie upgrade. No biggie, right? It doesn't necessarily mean the Oilers shouldn't have bet on Bouchard here. He is an important part of this team's window. But having two risky defensemen tying up almost $20 million in cap was always going to be a potential back-breaker. Contract grade: B+
